^Contreras PC, Takemori AE (June 1984). "Effect of prolyl-leucyl-glycinamide and alpha-melanocyte-stimulating hormone on levorphanol-induced analgesia, tolerance and dependence". Life Sciences. 34 (26): 2559–66.
doi:
10.1016/0024-3205(84)90041-9.
PMID6146083.
^Ehrensing RH, Kastin AJ, Michell GF (December 1984). "Antagonism of morphine analgesia by prolyl-leucyl-glycinamide (MIF-1) in humans". Pharmacology Biochemistry and Behavior. 21 (6): 975–8.
doi:
10.1016/S0091-3057(84)80083-0.
PMID6151672.
S2CID21761862.
^Galina ZH, Kastin AJ (December 1986). "Existence of antiopiate systems as illustrated by MIF-1/Tyr-MIF-1". Life Sciences. 39 (23): 2153–9.
doi:
10.1016/0024-3205(86)90391-7.
PMID2878336.
^Bocheva A, Dzambazova-Maximova E (November 2004). "Antiopioid properties of the TYR-MIF-1 family". Methods and Findings in Experimental and Clinical Pharmacology. 26 (9): 673–7.
doi:
10.1358/mf.2004.26.9.872564.
PMID15632952.
^Singhal RL, Rastogi RB (February 1982). "MIF-1: effects on norepinephrine, dopamine and serotonin metabolism in certain discrete brain regions". Pharmacology Biochemistry and Behavior. 16 (2): 229–33.
doi:
10.1016/0091-3057(82)90153-8.
PMID6122214.
S2CID44601791.
^Chiu P, Rajakumar G, Chiu S, Johnson RL, Mishra RK (1985). "Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG)". Peptides. 6 (2): 179–83.
doi:
10.1016/0196-9781(85)90036-1.
PMID2863809.
S2CID41473997.
^Xu DL, Yu WC, Pan GB, Chen SD (1987). "Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease". Advances in Neurology. 45: 587–90.
PMID2881450.
^Scimonelli T, Celis ME (1982). "Inhibition by L-prolyl-L-leucyl-glycinamide (PLG) of alpha-melanocyte stimulating hormone release from hypothalamic slices". Peptides. 3 (6): 885–9.
doi:
10.1016/0196-9781(82)90055-9.
PMID6132363.
S2CID3880592.
^McCullen RK, Peiffer RL, Jennes L, Hernandez DE (1988). "Inhibition by MIF-I of alpha-MSH induced increase of intraocular pressure and miosis in rabbits". Neuropeptides. 12 (4): 213–7.
doi:
10.1016/0143-4179(88)90057-1.
PMID2907121.
S2CID54378746.
^Caballero C, Celis ME (May 1993). "The effect of the blockade of alpha-melanocyte-stimulating hormone on LH release in the rat". The Journal of Endocrinology. 137 (2): 197–202.
doi:
10.1677/joe.0.1370197.
PMID8100849.
^Sandyk R (May 1990). "MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 in movement disorders". The International Journal of Neuroscience. 52 (1–2): 59–65.
doi:
10.3109/00207459008994244.
PMID1979968.
^Pignatiello MF, Olson GA, Kastin AJ, Ehrensing RH, McLean JH, Olson RD (March 1989). "MIF-1 is active in a chronic stress animal model of depression". Pharmacology Biochemistry and Behavior. 32 (3): 737–42.
doi:
10.1016/0091-3057(89)90027-0.
PMID2568001.
S2CID27994919.
^Kostowski W, Danysz W, Dyr W, Jankowska E, Krzaścik P, Pałejko W, Stefański R, Płaźnik A (1991). "MIF-1 potentiates the action of tricyclic antidepressants in an animal model of depression". Peptides. 12 (5): 915–8.
doi:
10.1016/0196-9781(91)90037-p.
PMID1686934.
S2CID3846846.
^Ehrensing RH, Kastin AJ, Wurzlow GF, Michell GF, Mebane AH (August 1994). "Improvement in major depression after low subcutaneous doses of MIF-1". Journal of Affective Disorders. 31 (4): 227–33.
doi:
10.1016/0165-0327(94)90098-1.
PMID7989637.
^Stratton LO, Kastin AJ (1975). "Increased acquisition of a complex appetitive task after MSH and MIF". Pharmacology Biochemistry and Behavior. 3 (5): 901–4.
doi:
10.1016/0091-3057(75)90124-0.
PMID1801.
S2CID7471749.
^Davis JL, Pico RM, Cherkin A (November 1982). "Memory enhancement induced in chicks by L-prolyl-L-leucyl-glycinamide". Pharmacology Biochemistry and Behavior. 17 (5): 893–6.
doi:
10.1016/0091-3057(82)90467-1.
PMID6129646.
S2CID33757710.
^d'Amore A, Pieretti S, Palazzesi S, Pezzini G, Chiarotti F, Scorza T, Loizzo A (1990). "MIF-1 can accelerate neuromotor, EEG and behavioral development in mice". Peptides. 11 (3): 527–32.
doi:
10.1016/0196-9781(90)90054-9.
PMID1974348.
S2CID29413931.
^Kastin AJ, Ehrensing RH, Olson RD, Coy DH (1980). "Neurological effects of MIF-1, MSH, and opiate peptides in clinical studies". International Journal of Neurology. 14 (2–4): 205–9.
PMID6152908.
^Katzenschlager R, Jackson MJ, Rose S, Stockwell K, Tayarani-Binazir KA, Zubair M, Smith LA, Jenner P, Lees AJ (April 2007). "Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets". Movement Disorders. 22 (5): 715–9.
doi:
10.1002/mds.21256.
PMID17373723.
S2CID32101673.
^Castellano JM, Batrynchuk J, Dolbeare K, Verma V, Mann A, Skoblenick KJ, Johnson RL, Mishra RK (October 2007). "MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats". Peptides. 28 (10): 2009–15.
doi:
10.1016/j.peptides.2007.07.026.
PMID17766011.
S2CID12114315.
^Banks WA, Kastin AJ (January 1994). "Opposite direction of transport across the blood–brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine". Peptides. 15 (1): 23–9.
doi:
10.1016/0196-9781(94)90165-1.
PMID7912427.
S2CID3851330.
^Kastin AJ, Hahn K, Zadina JE, Banks WA, Hackler L (April 1995). "Melanocyte-stimulating hormone release-inhibiting factor-1 (MIF-1) can be formed from Tyr-MIF-1 in brain mitochondria but not in brain homogenate". Journal of Neurochemistry. 64 (4): 1855–9.
doi:
10.1046/j.1471-4159.1995.64041855.x.
PMID7891114.
S2CID2655168.
^Contreras PC, Takemori AE (June 1984). "Effect of prolyl-leucyl-glycinamide and alpha-melanocyte-stimulating hormone on levorphanol-induced analgesia, tolerance and dependence". Life Sciences. 34 (26): 2559–66.
doi:
10.1016/0024-3205(84)90041-9.
PMID6146083.
^Ehrensing RH, Kastin AJ, Michell GF (December 1984). "Antagonism of morphine analgesia by prolyl-leucyl-glycinamide (MIF-1) in humans". Pharmacology Biochemistry and Behavior. 21 (6): 975–8.
doi:
10.1016/S0091-3057(84)80083-0.
PMID6151672.
S2CID21761862.
^Galina ZH, Kastin AJ (December 1986). "Existence of antiopiate systems as illustrated by MIF-1/Tyr-MIF-1". Life Sciences. 39 (23): 2153–9.
doi:
10.1016/0024-3205(86)90391-7.
PMID2878336.
^Bocheva A, Dzambazova-Maximova E (November 2004). "Antiopioid properties of the TYR-MIF-1 family". Methods and Findings in Experimental and Clinical Pharmacology. 26 (9): 673–7.
doi:
10.1358/mf.2004.26.9.872564.
PMID15632952.
^Singhal RL, Rastogi RB (February 1982). "MIF-1: effects on norepinephrine, dopamine and serotonin metabolism in certain discrete brain regions". Pharmacology Biochemistry and Behavior. 16 (2): 229–33.
doi:
10.1016/0091-3057(82)90153-8.
PMID6122214.
S2CID44601791.
^Chiu P, Rajakumar G, Chiu S, Johnson RL, Mishra RK (1985). "Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG)". Peptides. 6 (2): 179–83.
doi:
10.1016/0196-9781(85)90036-1.
PMID2863809.
S2CID41473997.
^Xu DL, Yu WC, Pan GB, Chen SD (1987). "Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease". Advances in Neurology. 45: 587–90.
PMID2881450.
^Scimonelli T, Celis ME (1982). "Inhibition by L-prolyl-L-leucyl-glycinamide (PLG) of alpha-melanocyte stimulating hormone release from hypothalamic slices". Peptides. 3 (6): 885–9.
doi:
10.1016/0196-9781(82)90055-9.
PMID6132363.
S2CID3880592.
^McCullen RK, Peiffer RL, Jennes L, Hernandez DE (1988). "Inhibition by MIF-I of alpha-MSH induced increase of intraocular pressure and miosis in rabbits". Neuropeptides. 12 (4): 213–7.
doi:
10.1016/0143-4179(88)90057-1.
PMID2907121.
S2CID54378746.
^Caballero C, Celis ME (May 1993). "The effect of the blockade of alpha-melanocyte-stimulating hormone on LH release in the rat". The Journal of Endocrinology. 137 (2): 197–202.
doi:
10.1677/joe.0.1370197.
PMID8100849.
^Sandyk R (May 1990). "MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 in movement disorders". The International Journal of Neuroscience. 52 (1–2): 59–65.
doi:
10.3109/00207459008994244.
PMID1979968.
^Pignatiello MF, Olson GA, Kastin AJ, Ehrensing RH, McLean JH, Olson RD (March 1989). "MIF-1 is active in a chronic stress animal model of depression". Pharmacology Biochemistry and Behavior. 32 (3): 737–42.
doi:
10.1016/0091-3057(89)90027-0.
PMID2568001.
S2CID27994919.
^Kostowski W, Danysz W, Dyr W, Jankowska E, Krzaścik P, Pałejko W, Stefański R, Płaźnik A (1991). "MIF-1 potentiates the action of tricyclic antidepressants in an animal model of depression". Peptides. 12 (5): 915–8.
doi:
10.1016/0196-9781(91)90037-p.
PMID1686934.
S2CID3846846.
^Ehrensing RH, Kastin AJ, Wurzlow GF, Michell GF, Mebane AH (August 1994). "Improvement in major depression after low subcutaneous doses of MIF-1". Journal of Affective Disorders. 31 (4): 227–33.
doi:
10.1016/0165-0327(94)90098-1.
PMID7989637.
^Stratton LO, Kastin AJ (1975). "Increased acquisition of a complex appetitive task after MSH and MIF". Pharmacology Biochemistry and Behavior. 3 (5): 901–4.
doi:
10.1016/0091-3057(75)90124-0.
PMID1801.
S2CID7471749.
^Davis JL, Pico RM, Cherkin A (November 1982). "Memory enhancement induced in chicks by L-prolyl-L-leucyl-glycinamide". Pharmacology Biochemistry and Behavior. 17 (5): 893–6.
doi:
10.1016/0091-3057(82)90467-1.
PMID6129646.
S2CID33757710.
^d'Amore A, Pieretti S, Palazzesi S, Pezzini G, Chiarotti F, Scorza T, Loizzo A (1990). "MIF-1 can accelerate neuromotor, EEG and behavioral development in mice". Peptides. 11 (3): 527–32.
doi:
10.1016/0196-9781(90)90054-9.
PMID1974348.
S2CID29413931.
^Kastin AJ, Ehrensing RH, Olson RD, Coy DH (1980). "Neurological effects of MIF-1, MSH, and opiate peptides in clinical studies". International Journal of Neurology. 14 (2–4): 205–9.
PMID6152908.
^Katzenschlager R, Jackson MJ, Rose S, Stockwell K, Tayarani-Binazir KA, Zubair M, Smith LA, Jenner P, Lees AJ (April 2007). "Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets". Movement Disorders. 22 (5): 715–9.
doi:
10.1002/mds.21256.
PMID17373723.
S2CID32101673.
^Castellano JM, Batrynchuk J, Dolbeare K, Verma V, Mann A, Skoblenick KJ, Johnson RL, Mishra RK (October 2007). "MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats". Peptides. 28 (10): 2009–15.
doi:
10.1016/j.peptides.2007.07.026.
PMID17766011.
S2CID12114315.
^Banks WA, Kastin AJ (January 1994). "Opposite direction of transport across the blood–brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine". Peptides. 15 (1): 23–9.
doi:
10.1016/0196-9781(94)90165-1.
PMID7912427.
S2CID3851330.
^Kastin AJ, Hahn K, Zadina JE, Banks WA, Hackler L (April 1995). "Melanocyte-stimulating hormone release-inhibiting factor-1 (MIF-1) can be formed from Tyr-MIF-1 in brain mitochondria but not in brain homogenate". Journal of Neurochemistry. 64 (4): 1855–9.
doi:
10.1046/j.1471-4159.1995.64041855.x.
PMID7891114.
S2CID2655168.